Gagnon Securities LLC Raises Stake in QuidelOrtho Corporation $QDEL

Gagnon Securities LLC lifted its position in shares of QuidelOrtho Corporation (NASDAQ:QDEL) by 29.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 159,177 shares of the company’s stock after buying an additional 36,678 shares during the quarter. Gagnon Securities LLC owned approximately 0.23% of QuidelOrtho worth $4,546,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Hantz Financial Services Inc. grew its holdings in shares of QuidelOrtho by 50.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after buying an additional 362 shares in the last quarter. ProShare Advisors LLC lifted its holdings in shares of QuidelOrtho by 3.0% during the 4th quarter. ProShare Advisors LLC now owns 13,164 shares of the company’s stock worth $376,000 after acquiring an additional 388 shares during the period. State of Alaska Department of Revenue lifted its holdings in shares of QuidelOrtho by 1.1% during the 4th quarter. State of Alaska Department of Revenue now owns 38,333 shares of the company’s stock worth $1,093,000 after acquiring an additional 424 shares during the period. Moody National Bank Trust Division lifted its holdings in shares of QuidelOrtho by 1.0% during the 4th quarter. Moody National Bank Trust Division now owns 51,512 shares of the company’s stock worth $1,471,000 after acquiring an additional 526 shares during the period. Finally, California State Teachers Retirement System grew its holdings in shares of QuidelOrtho by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 62,188 shares of the company’s stock worth $1,792,000 after purchasing an additional 725 shares during the period. 99.00% of the stock is currently owned by hedge funds and other institutional investors.

QuidelOrtho Stock Up 0.3%

Shares of QuidelOrtho stock opened at $14.13 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33. The firm has a market cap of $963.52 million, a P/E ratio of -0.79 and a beta of 0.77. QuidelOrtho Corporation has a fifty-two week low of $9.92 and a fifty-two week high of $35.58. The business has a 50-day moving average price of $13.03 and a 200 day moving average price of $21.29.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The firm had revenue of $619.80 million during the quarter, compared to the consensus estimate of $665.23 million. During the same period in the prior year, the firm earned $0.74 earnings per share. The firm’s quarterly revenue was down 10.5% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, sell-side analysts forecast that QuidelOrtho Corporation will post 1.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on QDEL shares. Citigroup dropped their target price on QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Zacks Research downgraded QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 17th. Jefferies Financial Group downgraded QuidelOrtho from a “buy” rating to a “hold” rating and dropped their target price for the company from $35.00 to $12.50 in a report on Thursday, May 7th. UBS Group reiterated a “neutral” rating and set a $12.00 target price on shares of QuidelOrtho in a report on Thursday, May 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a report on Tuesday, April 21st. Three research analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $14.88.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.